Revvity income statement

In fiscal 2025, Revvity reported revenue of $2.86bn, up 3.7% on the year before, operating income of $357m (a 12.5% margin) and net income of $241m, or $2.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Revvity: income statement, annual
Fiscal year	2009Jan 2010	2010Jan 2011	2011Jan 2012	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Jan 2016	2016Jan 2017	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Jan 2021	2021Jan 2022	2022Jan 2023	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJul 2026
Revenue	1,551	1,704	1,919	2,115	2,158	2,237	2,105	2,116	2,257	2,778	2,884	3,783	3,828	3,312	2,751	2,755	2,856	2,912
Cost of revenue	852	946	—	—	—	—	—	—	—	1,437	—	—	—	—	—	—	—	—
Gross profit	699	761	848	963	976	1,005	964	1,013	1,074	1,341	1,396	2,110	2,434	1,990	—	—	—	—
Research and development	90	95	116	132	132	108	113	124	139	194	189	146	200	222	217	197	216	216
Selling, general and administrative	477	487	624	627	582	648	587	590	626	812	815	716	975	1,026	1,023	994	992	1,026
Operating income	116	158	91	103	228	165	251	295	296	324	362	867	1,258	743	301	347	357	359
Interest expense	16	16	25	46	50	36	38	42	44	67	64	50	—	104	99	96	92	94
Income before tax	100	166	64	55	164	124	209	244	297	258	237	800	1,204	652	183	316	268	261
Income tax	27	27	63	−16	−11	−6	20	28	140	20	9	170	314	139	3	33	28	23
Net income	82	391	8	70	167	158	212	234	293	238	228	728	943	569	693	270	241	238
Diluted EPS	$0.70	$3.31	$0.07	$0.61	$1.47	$1.39	$1.87	$2.12	$2.64	$2.13	$2.04	$6.49	$8.08	$4.50	$5.55	$2.20	$2.07	$2.10
Diluted shares (average)	117m	118m	114m	115m	114m	114m	113m	110m	111m	112m	112m	112m	117m	126m	125m	123m	117m	113m
EBITDA	197	247	202	228	355	275	356	395	401	504	576	1,069	1,570	1,170	732	775	762	602

US$ millions unless shown otherwise. Fiscal quarters.

Revvity: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Apr 2026	2026 Q2Jul 2026
Revenue	684	729	665	720	699	772	711	730
Cost of revenue	299	—	289	328	324	—	323	313
Gross profit	385	—	376	393	375	—	388	417
Research and development	49	49	54	53	51	58	58	49
Selling, general and administrative	238	244	250	249	242	252	254	279
Operating income	98	119	72	91	82	112	76	89
Interest expense	24	23	23	23	23	24	25	23
Income before tax	100	95	52	69	56	92	50	64
Income tax	7	6	11	13	8	−4	9	10
Net income	94	95	42	54	47	98	41	52
Diluted EPS	$0.77	$0.78	$0.35	$0.46	$0.40	$0.86	$0.36	$0.47
EBITDA	116	224	170	108	100	215	181	106

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PODD vs RVTY GMED vs RVTY QDEL vs RVTY

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Revvity's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Revvity.